

## A Study on p53 Expression Patterns and Patients Features: Descriptive Study

Abhilash N.P.\*, Swayam Prava Pradhan\*\*

\*Post Graduate \*\*Associate Professor, Dept. of Pathology, MKCG Medical College, Berhampur, Orissa.

### Abstract

*Introduction:* Among the most widely studied tumour suppressor gene are RB & p53 which express PRB retinoblastoma protein & p53 protein respectively. These proteins control cell cycle and are involved in the inhibition of cell proliferation. Mutation of these proteins produce uncontrolled cell proliferation. *Methodology:* The detailed history including the duration, site, onset, progression, personal habits and duration of those habits like smoking, beetle quid chewing were noted. The clinical diagnosis was recorded. *Results:* In our study, the most common location was tongue 48% followed by the BUCCAL mucosa of 34% and the least common was the floor of the mouth 6%. It was observed that 59% of the cases in the age group 50-60 year showed suprabasal p53 positivity. *Conclusion:* No significant association observed between P53 and age, smoking and tobacco use.

**Keywords:** Oral Lesions; P53; Tobacco.

### Introduction

Oral cancers are one of the 10 leading cancers in the world. However in India it is the one of the most common cancer and constitutes a major public health problem [1].

The suffering, disfigurement and death associated with oral cancer is definitely avoidable due to surgical accessibility, etiological factors and the precedence of precancerous lesions provides an excellent opportunity for early detection and control.

Oral cancers is the 6<sup>th</sup> most common in the world [2]. Of all the oropharyngeal malignancies reported & registered to SEER (surveillance, Epidemiology and research program of national cancer institute of U.S public health services) in U.S.A from 1973-1987 more than 95% were squamous cell carcinoma [3].

Among the most widely studied tumour suppressor

gene are Rb & p53 which express pRb retinoblastoma protein & p53 protein respectively. These proteins control cell cycle and are involved in the inhibition of cell proliferation. Mutation of these proteins produce uncontrolled cell proliferation.

The p53 protein was first identified in 1979 as transformation related protein [p3]. p53 is the most commonly mutated gene in human cancer. The p53 acts as transcription factor for cell cycle inhibitors such as p21 and cycle prevent cell from going beyond G1 phase of cell cycle, permitting DNA repair.

If repair is not possible, p53 induces apoptosis of these cells to avoid transmission of potentially carcinogenic information.

The p53 gene is inactivated in approximately half of the head and neck cancers. Aberrant expression of p53 has been reported in mild dysplasia by some authors [4].

Over expression of p53 and gene mutation have also been detected in oral epithelial dysplasia [OED] adjacent to OSCC.

The association of p53 gene mutation with OSCC were studied by several authors.

**Corresponding Author:** Abhilash N.P., Post Graduate, Dept. of Pathology, MKCG Medical College, Berhampur, Orissa - 760004.

E-mail: [abhi\\_sdumc@yahoo.co.in](mailto:abhi_sdumc@yahoo.co.in)

(Received on 14.01.2017, Accepted on 19.01.2017)

**Methodology**

All the patients referred to the department of pathology with oral lesions for histopathological examination from the department of surgery and ENT were included in our study. The detailed history including the duration, site, onset, progression, personal habits and duration of those habits like smoking, beetle quid chewing were noted. The clinical diagnosis was recorded.

*Inclusion Criteria*

Histopathologically diagnosed benign lesions, premalignant lesions & SCC were included in the study which consist of 33 cases of oral squamous cell carcinoma. (of which 14 were well differentiated, 14 moderately differentiated and 02 poorly differentiated) and 03 were verrucous carcinoma. 11 premalignant lesions and 08 were benign lesions of the oral cavity. These cases were subjected to routine H&E staining and p53 immunohistochemical staining.

*Exclusion Criteria*

- Mechanical, thermal injury.
- Drug induced oral ulcers.

- Vitamin B12 deficient oral ulcers and other patches.
- Iron deficiency anemia caused lesion/ ulcers.

Compiling the clinical history and diagnosis we got different types of oral growth in our department i.e Exophytic, endophytic, leukoplakic, erythroplakic and erythroplakic.

Histopathological examinations were done from tissue samples obtained by excisional, incisional and punch biopsy. Histopathological sections were routinely stained with haematoxylin eosin [H&E] and also p53 was done on same specimens.

**Results**

As depicted in the table 67% of the non abusers showed suprabasal p53 positivity as against 67 % of chronic abusers.

The above histogram shows that of the total 52 patients, 19 were chronic abusers, 15 were non abusers and in 09 cases showed no history.

In 13/20(65%) cases of chronic smokers suprabasal p53 positivity was seen compared to 52.2% in non smokers.

Above histogram shows that out of 52 patients, 13




Fig. 1: Staining pattern in relation to betel quid/ tobacco use

**Table 1:** Staining pattern in relation to betel quid/ tobacco use (p=0.181)

	Negative	P53 Basal	Supra Basal	Total No
No History	04 44%	03 33%	02 22%	09
Non Abuser	03 20%	02 13%	10 67%	15
Chronic Abuser	06 20%	03 11%	19 67%	28




Fig. 2: Staining pattern in relation to smoking

Table 2: Staining pattern in relation to Smoking

(p=0.165)

	Negative	P53 Basal	Suprabasal	Total No
No History	05 46%	03 27%	03 27%	11
Non Smoker	03 14%	07 33%	11 52%	21
Chronic Smoker	04 20%	03 15%	13 65%	20

were chronic smokers, 21 were non smokers and in 11 No history was available.

In our study, the most common location was tongue 48% followed by the buccal mucosa of 34% and the

least common was the floor of the mouth 6%.

In our study, the commonest location was tongue and the least common was the floor of mouth.

Table 3: Staining pattern According to location

(p=0.616)

	Negative	Basal	Suprabasal	Total No
Buccal Mucosa	03 17%	05 28%	10 55%	18
Tounge	08 32%	04 16%	13 52%	25
Floor Of Mouth	00	01 33%	02 67%	03
Palate	02 33%	00	04 67%	06




Fig. 3: Staining pattern According to location

**Table 4:** Staining pattern According to age group

Age Group	Negative	Basal	P53 Suprabasal	Total No of Cases
20-30	00	01	01	02
		50%	50%	
30-40	04	02	08	14
	29%	14%	57%	
40-50	02	02	06	10
	20%	20%	60%	
50-60	04	03	10	17
	24%	17%	59%	
60-70	01	00	02	03
	33.3%		66.6%	
70-80	02	00	04	06
	33.3%		66.6%	

**Table 5:** Staining pattern According to SEX

	Negative	P53 Basal	Suprabasal	Total No
Female	06	01	06	13
	46%	08%	46%	
Male	07	07	25	39
	18%	18%	64%	

It was observed that 59% of the cases in the age group 50-60 year showed suprabasal p53 positivity

As seen from the above table majority of cases in both gender showed suprabasal positivity 25% of females and 75% of males respectively with a 1:3 ratio.

## Discussion

In many studies including oral lesions the reported incidence of p53 expression has varied from 11- 85% probably as a result of substantial difference in technique used as well as varied oral habits practiced in different geographical regions and Races [5].

A high frequency of elevated levels of p53 protein in SCC of Head and neck has been reported [6].

In our study 26 cases out of 33 cases of oral SCC expressed p53 protein. Our results are similar as reported by kaur et al [7].

Immunopositivity of p53 in oral SCC & dysplastic lesion in patients with habit of reverse smoking was studied by Alvarez and found 74% p53 positive in dysplastic lesions. P53 positivity in reverse smokers and 78% in conventional smoker. This result confirms p53 in the premalignant lesion may be an early episode in the oral carcinogenesis.

An important finding in our work is strong p53 positivity is more in smokers (65%) 13/20 cases of chronic smokers this is consistent with Field et al [8] who analyzed the smoking history of 71 patients by logistic regression and found that smoking correlates

with p53 over expression. Similarly increase p53 positive cells were detected in patients with both betel quid chewing and smoking habits [9].

P53 was found to be positive in 72.7% of cases of leukoplakia by a study done by priya Kumar et al, their study involved subjects indulging in various form of tobacco use as smokeless, smoking and combination of both they concluded, study of mutation status of p53 may be of more prognostic significance [10].

Another study results by Murthy et al suggest that the detection of p52 by IHC in biopsy of betel quid/ tobacco induced oral precancerous lesions, has no significant relationship to their likely malignant transformation. Based on these results they have reported to conclude that p53 protein detection may serve as an intermediate biomarker of cancer risk [11].

In our study suprabasal staining observed in 67% (n=19) cases of abusers is lesser than non abusers. History was not available in 9 cases in betelquid & tobacco users.

Our study is contradictory to the previous study of Murthy et al.

In our study the expression of p53 by immunohistochemical analysis in SCC was seen in 78.7% cases which comprises of 12 cases of well differentiated SCC, 11 cases of Moderately differentiated SCC, 01 case of Poorly differentiated SCC.

An interesting observation was noted in the present study that highly differentiated tumour had a high p53 immunostaining while Poorly differentiated SCC showed significant weaker IHC expression of p53

compared with Well differentiated form. These results are consistent with other studies which have demonstrated; statistically significant correlation was between histological grade and p53 expression. This might be interpreted as most of the mutation in Poorly differentiated OSCC is truncating mutations which may lead to less protein production and absence of its reactivity in the nucleus which in turn indicate the aggressive nature of the poorly differentiating nature<sup>12,13</sup>.

### Conclusion

In the present study no statistically significant association was found between p53 expression pattern and various clinical parameters like age, sex, location, smoking and tobacco.

### References

1. Lima LA , Siva CG, Rabenhost SH, Association between human papilloma virus and SCC. A systematic review. J Bras Pathol Med Lab 2014; 50: 75-84.
2. Syrjanen S, Iodi G von Bultzingslowen I, Aliko A, Ardino P, Campisi G et al. Human papilloma virus in oral carcinoma and oral potentially malignant disorders. A systematic review. Oral Dis 2011; 17(suppl 1):58-72.
3. R. Sankaranarayanan, K. Ramadas, G. Thomas et al., "Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial," The Lancet, 2005; 365(9475):1927-1933.
4. Califano J et al. Genetic progression model for head and neck cancers, implication for field cancerization. Cancer. Res. 1996; 56:2488-2492.
5. Yukk, Zonation AM, et al, Familial head and neck cancers. Molecular analysis of new clinical entity laryngoscope 2002; 12:587-1593.
6. Partridge M. Oral Cancer: I. The genetic basis of the disease. Dent update 2000; 27:242-8.
7. Kaur J, et al. Prognostic significance of p53 protein over expression in betel & tobacco related oral oncogenesis. Int. J. Cancer 1990; 79:370-5.
8. Field J.K , et al. P53 expression & mutation in SCC of the Head & Neck. Expression with the patients use of tobacco & alcohol. Cancer detection Prev 1994; 18(3):197-208.
9. P.R. Murti, et al, p53 expression in oral precancer as a marker for malignant potential. J. Oral Pathol Med 1998; 27:191-6.
10. Kaur J ,et al. Over expression of p53 protein in betelquid and tobacco related human oral dysplasia and SCC. Int. J. Cancer 1999; 58:340-5.
11. Mirza T, et al. Molecular analysis of HPV and oncosuppression gene in tobacco related oral cancer. Pak. J. Oto laryng. 1998; 14:27-33
12. Yan JJ, Tzeng CC, Jin YT. Overexpression of p53 protein in squamous cell carcinoma of buccal mucosa and tongue in Taiwan: An immunohistochemical and clinicopathology study. J. Oral Pathol Med 1996; 25:55-9.
13. Vousden KH, et al. The cells response to p53. Nat Rev Cancer 2002; 2:594-604.